No Data
No Data
IGM Biosciences' Insiders' Timely Sale May Have Helped Mitigate 10% Dip in Share Price
BMO Capital Initiates Coverage On IGM Biosciences With Outperform Rating, Announces Price Target of $21
BMO Capital Initiates IGM Biosciences(IGMS.US) With Buy Rating, Announces Target Price $21
Stifel Maintains IGM Biosciences(IGMS.US) With Buy Rating, Raises Target Price to $27
Express News | IGM Biosciences Inc : Stifel Raises Target Price to $27 From $25
RBC Capital Reaffirms Their Buy Rating on IGM Biosciences (IGMS)